TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21975270

Group type: EXPERIMENTAL
Intervention: H5 DNA (4 mg) at day 0 followed by H5N1 monovalent inactivated vaccine (MIV; 90 μg) at 24 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: H5 DNA (4 mg) at day 0 followed by H5N1 MIV at week 4
Number of subjects: 81

Group type: COMPARATOR
Intervention: Two-dose regimen of H5N1 MIV with a 4 or 24 week interval
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: H5 DNA (4 mg) at day 0 followed by H5N1 MIV at week 24
Number of subjects: 81
Study: 18155496

Group type: EXPERIMENTAL
Intervention: Morinda citrifolia juice (MCJ)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 60
Study: 16442203

Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine nerve ablation (LUNA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Vaginal uterosacral ligament resection (VUSR)
Number of subjects: 80
Study: 14632330

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 22
Study: 10630453

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 35
Study: 9093646

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.10 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atracurium (0.50 mg.kg‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atracurium (0.16 mg.kg‐1) after Pancuronium
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pancuronium (0.03 mg.kg‐1)
Number of subjects: 30
Study: 1868024

Group type: EXPERIMENTAL
Intervention: Sequential combination chemotherapy: cyclophosphamide, doxorubicin, 5-fluorouracil, followed by cisplatin and hexamethylmelamine
Number of subjects: 301

Group type: COMPARATOR
Intervention: 3-drug combination alternating with the 2-drug combination every other month
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Prognostic index calculated for each patient
Number of subjects: 301
Study: 7133974

Group type: EXPERIMENTAL
Intervention: Pirprofen 200 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pirprofen 400 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Pentazocin 100 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 30339929

Group type: EXPERIMENTAL
Intervention: Self-distancing group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Self-immersed group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 27680540

Group type: EXPERIMENTAL
Intervention: DAS ≤2.4 (BeSt-study)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: DAS <1.6 (IMPROVED-study)
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Non-adherence in BeSt-study
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Non-adherence in IMPROVED-study
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: Non-adherence in both studies
Number of subjects: 1109

Group type: EXPERIMENTAL
Intervention: DAS <1.6 steered protocol
Number of subjects: 1109
Study: 25369587

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 120
Study: 23265757

Group type: COMPARATOR
Intervention: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of saline four hourly (single dose group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of amoxycillin 0.5 g four hourly (short course group)
Number of subjects: 60
Study: 20608879

Group type: EXPERIMENTAL
Intervention: Transdermal patch with two drug-containing layers (20% and 80% concentrations) and a barrier layer (14% thickness)
Number of subjects: 0
Study: 19185242

Group type: EXPERIMENTAL
Intervention: epi‐Shugarcaine solution (epinephrine 0.025% and lidocaine 0.75% in fortified balanced salt solution [BSS Plus])
Number of subjects: 42

Group type: COMPARATOR
Intervention: Lundberg and Behndig's intracameral dilation solution (cyclopentolate 0.1%, phenylephrine 1.5%, and lidocaine 1%)
Number of subjects: 42
Study: 17332444

Group type: EXPERIMENTAL
Intervention: Mental practice (MP) sessions, 30 minutes, 2 days/week for 6 weeks, directly after therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham intervention (relaxation), same therapist interaction as MP group
Number of subjects: 32
Study: 15026102

Group type: EXPERIMENTAL
Intervention: Usual care plus an individually tailored and administered educational intervention promoting safe-driving strategies
Number of subjects: 403

Group type: COMPARATOR
Intervention: Usual care (comprehensive eye examination)
Number of subjects: 403
Study: 11490107

Group type: EXPERIMENTAL
Intervention: Early supported discharge and continued rehabilitation at home
Number of subjects: 83

Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 83
Study: 10649160

Group type: EXPERIMENTAL
Intervention: Twice-weekly fetal surveillance
Number of subjects: 167

Group type: COMPARATOR
Intervention: Fortnightly fetal surveillance
Number of subjects: 167
Study: 9150703

Group type: EXPERIMENTAL
Intervention: Lanreotide (LRT) 0.04 g i.m. once every 2 weeks for 3 months
Number of subjects: 5

Group type: COMPARATOR
Intervention: Water injection i.m. once every 2 weeks for 3 months (Control)
Number of subjects: 5
Study: 8103874

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (100 mg over 3 h)
Number of subjects: 5711

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5711
Study: 3789690

Group type: EXPERIMENTAL
Intervention: Alc A (60% isopropyl alcohol with emollients)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: CHG (4% chlorhexidine gluconate and 4% IPA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IPA (70% isopropyl alcohol)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alc B (70% IPA and 0.5% chlorhexidine gluconate with emollients)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (nonantiseptic liquid soap)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All antiseptics
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subject assessment of effects of hand washing
Number of subjects: 50
Study: 30166409

Group type: EXPERIMENTAL
Intervention: Humidified CPAP (10 cm H2O)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-humidified CPAP (10 cm H2O)
Number of subjects: 15
Study: 27131462

Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin levels
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 572
Study: 24499812

Group type: EXPERIMENTAL
Intervention: Salpingotomy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Salpingotomy and Salpingectomy
Number of subjects: 446
Study: 22275250

Group type: EXPERIMENTAL
Intervention: Short Rep1 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long Rep1 genotype
Number of subjects: 0

Group type: COMPARATOR
Intervention: Head injury
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head injury in those with long Rep1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Head injury and long Rep1
Number of subjects: 0
Study: 20049907

Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Number of subjects: 255
Study: 18686764

Group type: EXPERIMENTAL
Intervention: Self-etch adhesive Xeno III with microhybrid resin composite Esthet-X
Number of subjects: 60

Group type: COMPARATOR
Intervention: Etch-and-rinse adhesive OptiBond Solo Plus with Point 4 microhybrid resin composite
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 16194792

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study: 12911119

Group type: EXPERIMENTAL
Intervention: HFA-BDP extrafine aerosol (maximum 800 microg/day)
Number of subjects: 716
Study: 10478227

Group type: EXPERIMENTAL
Intervention: ECG gating
Number of subjects: 35
Study: 8712129

Group type: EXPERIMENTAL
Intervention: First-phase polarity of biphasic waveform
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-phase polarity of biphasic waveform
Number of subjects: 0
Study: 1919305

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg administered 10 minutes after 5 mg epidural morphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study: 30265882

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) - 3 doses of 2g at 4, 10, and 16 hours postoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (TXA) - 3 doses of 1g at 6, 12, and 18 hours postoperatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (oral and intravenous TXA)
Number of subjects: 0
Study: 27597724

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 every five days for 3 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 24691394

Group type: EXPERIMENTAL
Intervention: 3-week online face-training program targeting holistic face processing
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3-week online face-training program targeting holistic face processing (for 'better' trainees)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Self-reported diary improvements
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waiting period (control group)
Number of subjects: 24
Study: 22694488

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 37
Study: 20379947

Group type: EXPERIMENTAL
Intervention: Modified mesh materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraabdominal meshes, parastomal meshes, meshes in areas with bacterial contamination, meshes in the hiatus region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control assessments of explanted implant failures
Number of subjects: 0
Study: 18342952

Group type: EXPERIMENTAL
Intervention: Usual care with antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care without antidepressants
Number of subjects: 0
Study: 16377699

Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg loading dose followed by 50 mg maintenance dose of BAL4815)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BAL8557 (200 mg loading dose followed by 100 mg maintenance dose of BAL4815)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12729001

Group type: EXPERIMENTAL
Intervention: Amino acid mixture (5.6 g twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10910479

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.2 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 75
Study: 8902961

Group type: EXPERIMENTAL
Intervention: Back school program (Group 1, n = 74)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Video group (Group II, n = 64)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group (Group III, n = 67)
Number of subjects: 205
Study: 1528643

Group type: EXPERIMENTAL
Intervention: Acellular pertussis-diphtheria tetanus toxoids vaccine (APDT)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Whole cell DTP vaccine
Number of subjects: 397
Study: 4067799

Group type: EXPERIMENTAL
Intervention: Experimental group (responses different than test 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (repeated test 1 answers)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 30932300

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 101
Study: 29228087

Group type: EXPERIMENTAL
Intervention: ramucirumab + FOLFIRI
Number of subjects: 1072

Group type: COMPARATOR
Intervention: placebo + FOLFIRI
Number of subjects: 1072
Study: 26923773

Group type: EXPERIMENTAL
Intervention: Carprofen (2.2 mg/kg per os every 12 hours for 7 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo gel capsule (per os every 12 hours for 7 days)
Number of subjects: 12
Study: 25270900

Group type: EXPERIMENTAL
Intervention: TTM33 (33°C)
Number of subjects: 171

Group type: COMPARATOR
Intervention: TTM36 (36°C)
Number of subjects: 171
Study: 22382633

Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a (180 μg) plus ribavirin
Number of subjects: 201

Group type: COMPARATOR
Intervention: PegIFNα‐2b (60-150 μg) plus ribavirin
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a (180 μg) plus ribavirin in IL28B TT genotype patients
Number of subjects: 201

Group type: COMPARATOR
Intervention: PegIFNα‐2b (60-150 μg) plus ribavirin in IL28B TT genotype patients
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a (180 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Number of subjects: 201

Group type: COMPARATOR
Intervention: PegIFNα‐2b (60-150 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Number of subjects: 201
Study: 20635030

Group type: EXPERIMENTAL
Intervention: Vitapex paste
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paper points of povidone iodine
Number of subjects: 90
Study: 17651479

Group type: COMPARATOR
Intervention: Conventional quadruple therapy (QT) - omeprazole 20 mg bid, bismuth citrate 120 mg qid, tetracycline 500 mg qid, metronidazole 500 mg tid for 7 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Rifabutin-based triple therapy (OAR) - omeprazole 20 mg bid, amoxicillin 1 gr bid, rifabutin 150 mg bid for 7 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional quadruple therapy (QT)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Rifabutin-based triple therapy (OAR)
Number of subjects: 99
Study: 16093415

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Pairwise therapy
Number of subjects: 26
Study: 12116728

Group type: EXPERIMENTAL
Intervention: 1100 ppm sodium fluoride dentifrice
Number of subjects: 1334
Study: 10442360

Group type: EXPERIMENTAL
Intervention: UFT plus oral calcium folinate
Number of subjects: 473

Group type: COMPARATOR
Intervention: 5-FU plus calcium folinate
Number of subjects: 473
Study: 7844595

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular ASNase (25,000 IU/m2) weekly (n = 8)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard-dose intramuscular ASNase (10,000 IU/m2) every 3 days (n = 12)
Number of subjects: 20
Study: 2332001

Group type: EXPERIMENTAL
Intervention: 2D echo-Doppler (ED)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cardiac catheterization (CATH)
Number of subjects: 56
Study: 367433

Group type: EXPERIMENTAL
Intervention: Topical pindolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous pindolol
Number of subjects: 6
Study: 31060917

Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB) combined with Posterior Capsular Infiltration (PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multimodal periarticular infiltration analgesia
Number of subjects: 0
Study: 28584014

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in systolic blood pressure (SBP)
Number of subjects: 9114
Study: 26303187

Group type: EXPERIMENTAL
Intervention: Compression bandaging (CB) and physical exercises
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy (CDT) including Vodder II Manual Lymph Drainage
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (CB and CDT)
Number of subjects: 60
Study: 23903526

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 21340560

Group type: EXPERIMENTAL
Intervention: Provox HME®
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 60
Study: 18651150

Group type: EXPERIMENTAL
Intervention: 3D isotropic MRI T2‐weighted sequence (3D T2 ISO)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 2D TSE T2‐weighted sequence (2D T2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Correlation with IIEF‐5 score using 3D T2 ISO
Number of subjects: 53
Study: 17114146

Group type: EXPERIMENTAL
Intervention: Tinnitus Masking (TM)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 123
Study: 14756231

Group type: EXPERIMENTAL
Intervention: Enriched Air Nitrox 36% (oxygen 36%, nitrogen 64%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Air
Number of subjects: 11
Study: 10371376

Group type: COMPARATOR
Intervention: Normal sodium diet (235 mEq/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Moderate salt restriction (75 mEq/day)
Number of subjects: 8
Study: 8964113

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of vitamin C (2 g) and vitamin E (100 and 800 U)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smoking cessation (3 weeks)
Number of subjects: 0
Study: 1803141

Group type: EXPERIMENTAL
Intervention: Endonasal calcitrin (3 units twice a day for 1-1.5 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular calcitrin (not specified)
Number of subjects: 0
Study: 6438672

Group type: EXPERIMENTAL
Intervention: Diazepam (10-160 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxazepam (30-480 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (160 mg)
Number of subjects: 0
Study: 31203202

Group type: EXPERIMENTAL
Intervention: Intervention cohort (toolkit implemented)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Historic cohort (no intervention)
Number of subjects: 107
Study: 29322164

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (0.1 mg/d) plus intermittent micronized progesterone (200 mg/d for 12 days every 3 months)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol plus intermittent micronized progesterone (TE+IMP)
Number of subjects: 172
Study: 26703413

Group type: EXPERIMENTAL
Intervention: Simulation-based educational intervention (50-minute workshop on speaking up)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 71
Study: 24248549

Group type: EXPERIMENTAL
Intervention: Solid lag screws
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Telescoping screws
Number of subjects: 45
Study: 22103635

Group type: EXPERIMENTAL
Intervention: SumaRT/Nap (85mg sumatriptan and 500mg naproxen sodium)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: BCM (50mg butalbital, 325mg acetaminophen, 40mg caffeine)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study: 20017668

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical cohort analysis and prospective clinical intervention studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of pharmacogenomic therapy into practice
Number of subjects: 0
Study: 17577005

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (6 trials, 2900 participants)
Number of subjects: 28044

Group type: COMPARATOR
Intervention: Antiplatelet agents (8 trials, 4876 participants)
Number of subjects: 28044

Group type: COMPARATOR
Intervention: Adjusted-dose warfarin (12 trials, 12,963 participants)
Number of subjects: 28044

Group type: COMPARATOR
Intervention: Antithrombotic therapy (general)
Number of subjects: 28044
Study: 15829425

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) from day 1 to day 15
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) from day 8 to day 15 after placebo from day 1 to day 7
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo from day 1 to day 15
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Placebo from day 1 to day 7 and probiotics from day 8 to day 15
Number of subjects: 30
Study: 12477523

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Triptorelin
Number of subjects: 52
Study: 10091511

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol via Turbohaler
Number of subjects: 99

Group type: COMPARATOR
Intervention: 50 micrograms salmeterol via Diskus
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol Turbohaler b.i.d.
Number of subjects: 99

Group type: COMPARATOR
Intervention: 50 micrograms salmeterol Diskus b.i.d.
Number of subjects: 99
Study: 7759224

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 12
Study: 2672936

Group type: EXPERIMENTAL
Intervention: Isomeride plus diet
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 1315
Study: 708998

Group type: EXPERIMENTAL
Intervention: Normal diet with 100 mmol supplementary sodium chloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normal diet with 96 mmol supplementary potassium chloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 12
Study: 30987577

Group type: EXPERIMENTAL
Intervention: Postoperative urinary NGAL at 48 hours >156ng/mL
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 24 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 48 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 72 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Urinary NGAL concentrations at 96 hours
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier plot for survival
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Additive EuroSCORE, age, current smoking, and post-operative antibiotics usage
Number of subjects: 125